FutureCeuticals and Aura Scientific Resolve Patent Dispute and Launch CognatiQ for Cognitive Health

FutureCeuticals and Aura Scientific Settle Patent Dispute

On September 3, 2026, FutureCeuticals, Inc. (FC) and Aura Scientific (Aura) jointly announced a significant resolution to their ongoing patent and trademark dispute regarding the cognitive health ingredient NeuroRush® and the coffee fruit extract marketed by FC under the names CognatiQ® and NeuroFactor®. This agreement is poised to not only conclude the conflict but also to pave the way for a promising relationship between the two companies moving forward.

The Implications of the Settlement

The settlement marks an important milestone for FutureCeuticals, as their Vice President and General Counsel, J. Randal Wexler, expressed satisfaction with Aura's recognition of FC's valid patent rights. Wexler highlighted how protecting intellectual property is crucial for sustaining continual investments in clinical research and innovation. He noted that the resolution reinforces FutureCeuticals' standing in the cognitive health sector.

While this marks the end of NeuroRush® for Aura Scientific, it simultaneously signals the beginning of a strategic shift towards CognatiQ®. Kyle Seymour, Aura's Product Development Director, underlined the excitement surrounding the introduction of CognatiQ®, emphasizing that it offers a comparable alternative to NeuroRush®, while benefitting from FutureCeuticals' extensive clinical support and scientific expertise.

Shaping Future Collaborations

Wexler characterized the resolution as a win-win for both organizations, suggesting that it opens new avenues for collaboration and product development. With Aura's strengthened market presence and logistical capabilities, the partnership aligns well with FutureCeuticals' commitment to support brands looking for effective health-boosting ingredients.

"We look forward to exploring opportunities related to differentiated ingredients backed by clinical data," Wexler added. This collaboration is anticipated to set a fresh paradigm in the wellness industry, focusing on clinically-supported innovations that meet the evolving needs of consumers.

Furthermore, Seymour acknowledged FutureCeuticals' willingness to engage in constructive collaboration, noting that their mutual goal is to leverage Aura's customer-centric approach and product development experience alongside FutureCeuticals' diverse portfolio and scientific backing. He believes that such collaborations could open new doors not only for their companies but also for the wellness market as a whole.

FutureCeuticals' Role in the Market

With an established reputation as a leading player in the research, development, and manufacturing of fruit, vegetable, and grain-based powders and extracts, FutureCeuticals continues to be at the forefront of innovation. Their offerings, including CognatiQ® and NeuroFactor®, are currently available exclusively through FutureCeuticals, further emphasizing their expertise in the field.

About Aura Scientific

Aura Scientific stands out in the nutraceutical sector for its commitment to innovation. They are actively engaged in the research, development, and marketing of distinguished nutraceutical ingredients aimed at dietary supplements. Their products, which include EndoFlo™ and ProtoTest™, are specifically developed to meet consumer well-being applications.